New Insights into Human Cytomegalovirus pUL52 Structure.
DNA-packaging
human cytomegalovirus
pUL52
terminase
viral targets
Journal
Viruses
ISSN: 1999-4915
Titre abrégé: Viruses
Pays: Switzerland
ID NLM: 101509722
Informations de publication
Date de publication:
18 08 2021
18 08 2021
Historique:
received:
01
07
2021
revised:
02
08
2021
accepted:
14
08
2021
entrez:
28
8
2021
pubmed:
29
8
2021
medline:
29
1
2022
Statut:
epublish
Résumé
Human cytomegalovirus (HCMV) can cause serious diseases in immunocompromised patients. Current antiviral inhibitors all target the viral DNA polymerase. They have adverse effects, and prolonged treatment can select for drug resistance mutations. Thus, new drugs targeting other stages of replication are an urgent need. The terminase complex (pUL56-pUL89-pUL51) is highly specific, has no counterpart in the human organism, and thus represents a target of choice for new antivirals development. This complex is required for DNA processing and packaging. pUL52 was shown to be essential for the cleavage of concatemeric HCMV DNA and crucial for viral replication, but its functional domains are not yet identified. Polymorphism analysis was performed by sequencing
Identifiants
pubmed: 34452502
pii: v13081638
doi: 10.3390/v13081638
pmc: PMC8402748
pii:
doi:
Substances chimiques
Acetates
0
Antiviral Agents
0
Quinazolines
0
Viral Proteins
0
letermovir
1H09Y5WO1F
Endodeoxyribonucleases
EC 3.1.-
pUL52 protein, human cytomegalovirus
EC 3.1.-
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Références
Antimicrob Agents Chemother. 2018 Aug 27;62(9):
pubmed: 29914965
Nucleic Acids Res. 2015 Jul 1;43(W1):W580-4
pubmed: 25845596
Mol Syst Biol. 2011 Oct 11;7:539
pubmed: 21988835
J Virol. 1999 Oct;73(10):8320-9
pubmed: 10482582
Antiviral Res. 2016 May;129:115-119
pubmed: 26872863
Nucleic Acids Res. 2015 Jul 1;43(W1):W174-81
pubmed: 25883148
J Gen Virol. 2000 Sep;81(Pt 9):2231-2244
pubmed: 10950981
Life (Basel). 2021 Feb 16;11(2):
pubmed: 33669389
J Virol. 1998 Mar;72(3):2463-73
pubmed: 9499108
J Virol. 2013 Feb;87(3):1720-32
pubmed: 23175377
J Virol. 2015 Dec;89(23):12221-5
pubmed: 26401033
Sci Rep. 2017 Aug 18;7(1):8796
pubmed: 28821882
Nat Protoc. 2010 Apr;5(4):725-38
pubmed: 20360767
Nat Methods. 2015 Jan;12(1):7-8
pubmed: 25549265
Curr Top Microbiol Immunol. 1990;154:125-69
pubmed: 2161319
J Mol Biol. 1967 Jun 14;26(2):365-9
pubmed: 4291934
J Virol. 2008 Mar;82(5):2065-78
pubmed: 18077717
Antiviral Res. 2017 Dec;148:1-4
pubmed: 29107686
J Virol. 1996 Jun;70(6):3938-46
pubmed: 8648731
Blood. 2016 Dec 8;128(23):2624-2636
pubmed: 27760756
Transpl Infect Dis. 2000 Sep;2(3):99-100
pubmed: 11429019
Clin Microbiol Rev. 2010 Oct;23(4):689-712
pubmed: 20930070
Viruses. 2019 Nov 26;11(12):
pubmed: 31779110
Antivir Ther. 2008;13(5):643-54
pubmed: 18771048
J Virol. 2016 Jun 10;90(13):5860-5875
pubmed: 27009952
J Virol. 2015 Jan;89(1):443-53
pubmed: 25320327
FEMS Microbiol Rev. 2018 Mar 1;42(2):137-145
pubmed: 29361041
Nucleic Acids Res. 2013 Jul;41(Web Server issue):W597-600
pubmed: 23671338
J Virol. 2016 Jun 10;90(13):5876-5885
pubmed: 27053556
Best Pract Res Clin Obstet Gynaecol. 2017 Jan;38:97-107
pubmed: 27923540
N Engl J Med. 2017 Dec 21;377(25):2433-2444
pubmed: 29211658